GlassScriptPhysician profile
Lewis Stolman
NPI 1396749321
$2,739.81
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $90.11 · 2021: $425 · 2022: $479 · 2023: $825 · 2024: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,571.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $459.03 | 2022-2024 | Skyrizi, Rinvoq |
| Amgen INC. | $297.20 | 2021-2024 | Otezla |
| Incyte Corporation | $277.33 | 2021-2024 | Opzelura |
| Ucb, INC. | $252.80 | 2019-2024 | Bimzelx, Cimzia |
| Leo Pharma INC. | $197.62 | 2019-2024 | Adbry |
| Mayne Pharma Commercial LLC | $173.85 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $138.78 | 2021-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $110.67 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $110.03 | 2023-2024 | Zoryve |
| Sun Pharmaceutical Industries INC. | $98.13 | 2019-2023 | Winlevi, Absorica Ld |
| Lilly USA, LLC | $96.20 | 2020-2022 | |
| Genzyme Corporation | $94.85 | 2021-2023 | |
| Dermavant Sciences, INC. | $75.19 | 2023-2024 | Vtama |
| Pfizer INC. | $65.57 | 2019-2024 | |
| Janssen Biotech, INC. | $60.18 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $56.98 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $31.77 | 2021-2022 | |
| Genentech USA, INC. | $18.10 | 2023 | Xolair |
| Pierre Fabre Pharmaceuticals, INC. | $15.39 | 2019 | |
| Prugen, INC. Pharmaceuticals | $14.86 | 2019 | |
| Dusa Pharmaceuticals, INC. | $14.29 | 2019 | |
| Sebela Pharmaceuticals INC. | $14.13 | 2022 | |
| Journey Medical Corporation | $13.89 | 2022 | |
| Biofrontera INC. | $13.66 | 2021 | |
| Epi Health, LLC | $13.58 | 2021 | |
| Kyowa Kirin, INC. | $13.22 | 2021 | |
| Dermira, INC. | $12.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lewis Stolman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.